Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: further erosion of pricing or some contained explosions?

November 14, 2024 7:51am

Little bit of each as econ and waiting for Jerome’s speech puts its mark on session

Earnings and News: BLUE, RGNX while Mesoblast (MESO) has issued 2 M unquoted warrants as part of a US$50 million convertible note facility, which the company can utilize following FDA approval. Each warrant can convert into one ordinary share or into American Depositary Receipts at a specified exchange rate.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

MY Pre-Open Thoughts: 3 Positive, 1 Negative and 2 Sell into Strength Indications

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

RegMed Investors (RMi) Closing Bell: an all but wipe-out of conviction … https://www.regmedinvestors.com/articles/13696

RegMed Investors (RMi) Research Note: Q3/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes … https://www.regmedinvestors.com/articles/13441

RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

Thursday: The pre-open Dow futures are UP +0.21% (+91 points), the S&P futures are UP +0.10% or (+5 points) and the Nasdaq futures are UP +0.05% or (+10 points)

U.S. stock futures rose slightly Thursday, 11/14
European markets moved higher,
Asia-Pacific markets mostly fall

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

On Wednesday, the Dow rose +0.11%, the S&P +0.02% gain while the Nasdaq ended down -0.26%.

Investors should be questioning the postelection rally following X-Pres. Donald Trump’s victory last week; does it still have room to run?

Economic Data Docket: October PPI (producer price index)

PPI, a measure of what producers get for goods and services, is expected to show a 0.2% increase last month, according to a Dow Jones consensus estimate. That’s up from no change in September; excluding volatile food and energy prices, it’s set to have increased 0.3%, up from 0.2% previously.

Q4/24: November 5 negative and 4 positive closes

October: 8 positive and 15 negative closes

Q3/24:

September – 10 positive and 10 negative close

August – I neutral, 10 positive and 11 negative closes
July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength

Wednesday, Tuesday, Monday, Friday and Thursday closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Mesoblast (MESO +$1.76 after Tuesday’s +$0.22 after Monday’s +$0.55 with a positive +$0.10 or +0.81% aftermarket

Ultragenyx Pharmaceuticals (RARE) closed up +$0.87 after Tuesday’s -$2.89 with a positive +$1.08 or +2.22% pre-open

Positive Indications:

Wednesday, Tuesday, Monday, Friday and Thursday closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Beam Therapeutics (BEAM) closed down -$0.44 after Tuesday’s -$2.41, Monday’s +$3.29, and last Friday’s +$0.96 with a positive +$0.68 or +2.47% aftermarket

CRISPR Therapeutics (CRSP) closed down -$0.94 after Tuesday’s -$4.13 and Monday’s +$3.24 with a positive +$0.42 or +0.84% pre-open

Intellia Therapeutics (NTLA) closed down -$0.54 after Tuesday’s -$0.85 and Monday’s +$0.77 with a positive +$0.19 or +1.18% pre-open

Negative Indication:

Wednesday, Tuesday, Monday, Friday and Thursday closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Ionis Pharmaceuticals (IONS) closed up +$0.01 after Tuesday’s -$1.11 and Monday’s -$0.31 with a negative -$0.07 or -0.19% pre-open

The BOTTOM LINE: are we hitting a pause as earnings and econs shift the table plate?

Ranking the end of October:

11/13 – Wednesday: closed negative with 8 incliner, 25 decliners and 2 flats
11/12 – Tuesday: closed negative with 7 incliner, 27 decliners and 1 flat
11/11 – Monday closed positive with 23 incliner, 11 decliners and 1 flat

11/8 – Friday: closed negative with 15 incliner, 18 decliners and 2 flats
11/7 – Thursday: closed negative with 11 incliner, 20 decliners and 4 flats
11/6 – Wednesday: closed positive with 26 incliner, 7 decliners and 2 flats
11/5 – Tuesday closed positive with 25 incliner, 8 decliners and 2 flats
11/4 – Monday closed negative with 15 incliner, 18 decliners and 2 flats

11/1 - Friday advance/decline line closed positive with 26 incliner, 7 decliners and 2 flats

Welcome to my world of defining the “grey’ in our universe!

The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.